Cencora Surges on Strong Earnings | Business and Finance News

Cencora just smashed Q2 earnings, hitting revenue targets and crushing profit expectations—thanks to its specialty pharma push, especially through OneOncology, and a digital overhaul that’s making operations smoother. The CEO highlighted their unique position to scale across healthcare. Analysts dug into Part B vs. Part D biosimilars (Part B’s higher margins come from infusion services) and asked if OneOncology’s rapid growth can sustain—answer: integration’s going strong with more value ahead. Watch for how their MSOs integrate, AI-driven forecasting, biosimilar policy shifts, and potential clinical trial expansions. Stock jumped post-report—market clearly loves the momentum and strategy. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/46e1555335d1b3fb